Showing 6 posts of 6 posts found.

GSK’s Ojjaara approved by FDA for patients with myelofibrosis and anaemia

September 18, 2023
Medical Communications FDA, GSK, Haematology, Ojjaara, anaemia, myelofibrosis

GSK has announced that the US Food and Drug Administration (FDA) has approved Ojjaara (momelotinib) for the treatment of intermediate …

Myelofibrosis market to increase to be worth over $1 billion by 2025

November 16, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EU, US, myelofibrosis

The myelofibrosis market is expected to grow from $545.2 million in 2015 to $1.02 billion by 2025, almost doubling in …

Bristol-Myers Squibb makes big pharma deals

September 1, 2015
Manufacturing and Production BMS, Bristol-Myers Squibb, PRM-151, Promedior, QIMR, fibrosis, idiopathic pulmonary fibrosis, immuno-oncology, myelofibrosis

Bristol-Myers Squibb is flexing its muscles in respiratory disease, by signing a deal to acquire the exclusive right to acquire …

Novartis’ myelofibrosis treatment approved in Europe

August 28, 2012
Sales and Marketing Incyte, Jakavi, Novartis, Orphan Drugs, myelofibrosis

Novartis’ Jakavi, a new treatment for patients with myelofibrosis has been approved in Europe. The drug was co-developed with Incyte, …

Novartis plans Q2 filing for blood cancer drug

March 17, 2011
Sales and Marketing COMFORT-II trial, INC424, Incyte, JAK, Janus kinase inhibitor, Novartis, blood cancer, cancer drug, myelofibrosis, ruxolitinib

Novartis will file ruxolitinib for worldwide regulatory approval in the second quarter after the cancer drug met its primary endpoint …

Novartis blood cancer drug impresses in late stage trial

December 22, 2010
Research and Development, Sales and Marketing INC424, Novartis, blood cancer, myelofibrosis, orphan drug

Novartis has released positive phase III results of its myelofibrosis drug INC424 showing it met its primary endpoint of reducing …

Latest content